Orphenadrine Citrate Extended-Release Tablets Rx
Generic Name and Formulations:
Orphenadrine citrate 100mg; sust-rel tabs.
Various generic manufacturers
Indications for Orphenadrine Citrate Extended-Release Tablets:
Painful musculoskeletal conditions.
100mg twice daily (AM and PM).
Glaucoma. Achalasia. GU or GI obstruction. Myasthenia gravis.
Coronary disease, insufficiency, or arrhythmias. Asthma (inj). Monitor blood, urine, and liver in long-term use. Pregnancy (Cat.C). Nursing mothers.
Potentiates anticholinergics, alcohol, other CNS depressants, MAOIs, antidepressants. Tremors, mental confusion with propoxyphene. Antagonizes steroids, barbiturates, phenylbutazone.
Tachycardia, transient dizziness or syncope, other anticholinergic effects (eg, weakness, increased intraocular pressure, urinary retention, blurred vision, dry mouth), GI upset.
Formerly known under the brand name Norflex.
Sign Up for Free e-newsletters
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- Handling Chemotherapy Premedications
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|